Capricor Therapeutics AI Stock Analysis
Capricor Therapeutics (4LN2) AI Stock Analysis
Capricor Therapeutics
(XETRA:4LN2)
No summary available
Capricor Therapeutics (4LN2) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 649.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,963
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- 1.19
- Revenue Growth
- -100.00%
- EPS Growth
- -40.84%
- Country
- Germany
- Employees
- 231
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Capricor Therapeutics Business Overview & Revenue Model
Company Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which re...
Capricor Therapeutics Earnings Call Summary
The call was predominantly positive, supported by a statistically significant HOPE-3 primary endpoint, favorable two-year extension and integrated-trial data, positive safety experience, cardiac-data recognition, FDA review progress, launch preparation, manufacturing readiness, and a cash runway of at least 12 months. Key negatives were the still-pending FDA decision, the ongoing NS Pharma dispute, no recognized revenue, higher operating expenses, larger net losses, a nonsignificant overall ejection-fraction result, and a 10% workforce reduction. The highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said the FDA review remains ongoing with the PDUFA target action date extended to November 22, 2026, after submission of an amendment containing approximately 30,000 pages, and the proposed refined indication is for patients with age greater than 9 years old; commercial readiness is underway across distribution, patient support, market access, medical affairs, and physician education, while the San Diego GMP facility is ready for an initial launch, with the first-floor clean room able to meet the needs of 250 patients per year or around 1000 doses per year and the second floor expected to support 2,000 to 2500 patients or up to 10,000 doses per year operating at full capacity, with validation targeted for the first half of 2020; the company estimates approximately 15,000 people in The US are living with DMD, roughly 2-thirds are ages 9 and older, expects arbitration to commence in mid-2027, reduced its workforce by approximately 10% in the third quarter, reported approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026, and believes its existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months.
Capricor Therapeutics Risk Analysis
Capricor Therapeutics disclosed 31 risk factors in its most recent earnings report. Capricor Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCapricor Therapeutics Peers Comparison
Overall Rating
ABEO50Neutral
LXEO50Neutral
RGNX50Neutral
RCKT45Neutral
SLDB42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ABEO | 50Neutral | $140.30M | -2.05 | -44.82% | ― | 9652.75% | -172.49% |
| LXEO | 50Neutral | $251.19M | -2.67 | -41.85% | ― | ― | 64.51% |
| RGNX | 50Neutral | $508.48M | -2.64 | -203.98% | ― | -4.59% | 8.03% |
| RCKT | 45Neutral | $268.95M | -15.50 | -5.76% | ― | ― | 93.45% |
| SLDB | 42Neutral | $800.25M | -4.25 | -67.78% | ― | ― | 28.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:4LN2 | Capricor Therapeutics, Inc. | 8.95 | 4.07 | 83.51% | |
| RCKT | Rocket Pharma | 2.48 | -0.69 | -21.77% | |
| ABEO | Abeona Therapeutics Inc | 2.30 | -2.23 | -49.23% | |
| RGNX | RegenXBio Inc. | 8.47 | -3.17 | -27.23% | |
| SLDB | Solid Biosciences | 7.60 | 3.30 | 76.74% | |
| LXEO | Lexeo Therapeutics, Inc. | 3.07 | -5.92 | -65.85% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.